Mostrar el registro sencillo del ítem
dc.contributor.author | Pineda-Tenor, Daniel | |
dc.contributor.author | Berenguer, Juan | |
dc.contributor.author | Garcia-Broncano, Pilar | |
dc.contributor.author | Jimenez-Sousa, Maria Angeles | |
dc.contributor.author | Fernandez-Rodriguez, Amanda | |
dc.contributor.author | Diez, Cristina | |
dc.contributor.author | Garcia-Alvarez, Monica | |
dc.contributor.author | Carrero, Ana | |
dc.contributor.author | Catalán, Pilar | |
dc.contributor.author | Aldámiz-Echevarria, Teresa | |
dc.contributor.author | Resino, Salvador | |
dc.date.accessioned | 2024-02-04T20:28:21Z | |
dc.date.available | 2024-02-04T20:28:21Z | |
dc.date.issued | 2014-05 | |
dc.identifier.citation | Eur J Clin Invest. 2014 May;44(5):453-62. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/17451 | |
dc.description.abstract | Background: The adiponectin (ADIPOQ) rs2241766 polymorphism is related to metabolic abnormalities. The aim of this study was to evaluate the association of the ADIPOQ rs2241766 polymorphism with serum dyslipidemia and insulin resistance (IR) in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients. Methods: We carried out a cross-sectional study on 262 patients. ADIPOQ rs2241766 polymorphisms were genotyped by GoldenGate® assay. Generalized linear models (GLMs) were used to compare continuous outcome variables (total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C and homeostatic model assessment (HOMA)) and categorical outcome variables (TC≥200 mg/dL, TG≥170 mg/dL, LDL-C≥100 mg/dL, HDL-C≤35 mg/dL, non-HDL-C≥120 mg/dL and HOMA≥3·8) according to ADIPOQ genotype under a dominant inheritance model. Results: Patients with the rs2241766 GG/GT genotype had significantly lower serum TC levels (P=0·038) and percentages of TC≥200 mg/dL (P=0·022) than rs2241766 TT carriers. When adjusted GLM was performed, rs2241766 GG/GT was associated with low serum TC levels (arithmetic mean ratio (AMR)=0·92 [(95% CI=0·85; 0·99) P=0·024]) and low likelihood of TC≥200 mg/dL (odds ratio (OR)=0·32 [(95% CI=0·11; 0·88) P=0·027]. When stratifying by steatosis, no significant values were found for patients without steatosis. However, for patients with steatosis, rs2241766 GG/GT genotypes were related to low TC serum values of TC (AMR=0·89; P=0·027), LDL-C (AMR=0·85; P=0·039) and non-HDL-C (AMR=0·86; P=0·015). No significant associations were found between rs2241766 and HOMA values. Conclusions: The presence of the ADIPOQ rs2241766 G allele (GG/GT genotype) was associated with a protective effect against dyslipidemia, primarily in HIV/HCV-coinfected patients with steatosis. | es_ES |
dc.description.sponsorship | This work has been supported by grants given by Fondo de Investigación de Sanidad en España (FIS) [Spanish Health Founds for Research] [grant numbers PI08/0738, PI11/00245, PI08/0928 and PI11/01556], Red Española de Investigación en SIDA (RIS) [AIDS Research Network] [grant numbers RD12/0017/0024 and RD12/0017/0004] and ‘Fundación para la Investigación y la Prevención del Sida en España’ (FIPSE) [grant number 361020/10]. DPT, PGB, MAJS, AFR, and MGA are supported by ‘Instituto de Salud Carlos III’ [grant numbers CM12/00043, FI12/00036, CM10/00105, PI11/00245, CD12/00442, respectively]. JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS) | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley | es_ES |
dc.type.hasVersion | AM | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Adiponectin | es_ES |
dc.subject | AIDS | es_ES |
dc.subject | Chronic hepatitis C | es_ES |
dc.subject | Dyslipidemia | es_ES |
dc.subject | Metabolic disturbance | es_ES |
dc.subject | SNPs | es_ES |
dc.subject.mesh | Adiponectin | es_ES |
dc.subject.mesh | Adult | es_ES |
dc.subject.mesh | Cholesterol, HDL | es_ES |
dc.subject.mesh | Cholesterol, LDL | es_ES |
dc.subject.mesh | Coinfection | es_ES |
dc.subject.mesh | Cross-Sectional Studies | es_ES |
dc.subject.mesh | Dyslipidemias | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | HIV Infections | es_ES |
dc.subject.mesh | Hepatitis C, Chronic | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Insulin Resistance | es_ES |
dc.subject.mesh | Male | es_ES |
dc.subject.mesh | Polymorphism, Genetic | es_ES |
dc.subject.mesh | Triglycerides | es_ES |
dc.title | Association of adiponectin (ADIPOQ) rs2241766 polymorphism and dyslipidemia in HIV/HCV-coinfected patients | es_ES |
dc.type | research article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 24528335 | es_ES |
dc.format.volume | 44 | es_ES |
dc.format.number | 5 | es_ES |
dc.format.page | 453-562 | es_ES |
dc.identifier.doi | 10.1111/eci.12250 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | RETICS-Sida (RIS-ISCIII) (España) | es_ES |
dc.contributor.funder | Fundación para la Investigación y la Prevención del Sida en España | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1365-2362 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1111/eci.12250 | es_ES |
dc.identifier.journal | European journal of clinical investigation | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//CD12%2F00442/ES/CD12%2F00442/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MICINN//PI11%2F00245/ES/Erradicación del VHC en pacientes coinfectados por VIH%2FVHC: efectos sobre la inflamación, el daño endotelial, la activación inmune y la aterosclerosis preclínica/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MICINN//CM10%2F00105/ES/CM10%2F00105/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//FI12%2F00036/ES/FI12%2F00036/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//CM12%2F00043/ES/CM12%2F00043/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD12%2F0017%2F0004/ES/SIDA/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD12%2F0017%2F0024/ES/SIDA/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MICINN//PI11%2F01556/ES/Erradicación del VHC en pacientes coinfectados por VIH%2FVHC: efectos sobre la inflamación, el daño endotelial, la activación inmune y la aterosclerosis preclínica/ | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI08/0928 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI08/0738 | es_ES |